AbCellera Results Presentation Deck

STRONG 17 GROWTH OF CORE BUSINESS Q3 2021. BUSINESS UPDATE SUMMARY. NEW programs under contract 9 NEW programs started 1 MOLECULE entered clinical testing 155 cumulative programs under contract $754M in cash, cash equivalents & marketable securities $44M in accounts & accrued receivable

View entire presentation